跳至主要内容
临床试验/NCT04119739
NCT04119739已完成4 期

Pain Reduction Produced by Physiotherapy, Ibuprofen, and the Absence of Treatment, in Carpal Tunnel Syndrome

Francisco Unda Solano1 个研究点 分布在 1 个国家目标入组 117 人开始时间: 2020年4月14日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
117
试验地点
1
主要终点
Distal upper limb pain

研究概览

简要总结

Pain reduction effects of the median nerve neural mobilization technique (a physiotherapy treatment) will be compared to those produced by a pharmaceutical treatment and the absence of treatment, in subjects who suffer carpal tunnel syndrome.

详细描述

The present randomized clinical trial will perform a comparison of the pain reduction effects produced by the application of median nerve neural mobilization (non invasive and non pharmaceutical physiotherapy treatment), to the pain reduction effect produced by an oral ibuprofen treatment or the lack of treatment (waiting list control group) in subjects diagnosed with carpal tunnel syndrome. Additionally, effects over the functionality of the affected upper limb will be evaluated and compared. Subjects will be invited to participate and randomly allocated to 3 different groups.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Participants must be medically diagnosed with unilateral carpal tunnel syndrome (with confirmative electrodiagnostic findings).
  • Full understanding of written and spoken Spanish (language).
  • Participants must freely consent to participate.
  • The presence of positive Phalen and Tinel signs.
  • The presence of carpal tunnel syndrome signs and symptoms

排除标准

  • The lack to meet inclusion criterions, the presence of cognitive impairment.
  • Upper limb surgery or trauma
  • Pregnancy
  • Deformities of the (affected) upper limb
  • Recent skin injuries or infections (in the affected upper limb)
  • Autoimmune inflammatory conditions or flu type symptoms.
  • Allergy to gabapentin, ibuprofen or ibuprofen arginine
  • Participants must not be (during the present investigation) under any type of pain reducing treatment (conservative, homeopathic, invasive or not invasive).
  • Metabolic neuropathy.
  • Obesity (body mass index over 30).
  • Participants who are not employed.

研究组 & 干预措施

Median nerve neural mobilization

Experimental

Non pharmaceutical, non invasive, physiotherapy technique; which consists of a passive and repetitive upper limb movement that seeks to induced median nerve gliding and incursions against surrounding connective tissue. Subjects will be treated 5 days per week during a total time lapse of 4 weeks.

干预措施: Median nerve neural mobilization (Other)

Ibuprofen Arginine

Active Comparator

Oral tablet pharmaceutical treatment. Participants will be treated with a maximum of 1200 mg per day, subdivided in 3 intakes of 400 mg each 8 hours during a time lapse of 4 weeks.

干预措施: Ibuprofen Arginine (Drug)

结局指标

主要结局

Distal upper limb pain

时间窗: Changes from baseline (measured immediately before the application of the first treatment) and 40 minutes after the application of the last treatment.

Assessed through the visual analog scale (VAS). The VAS is a psychometric response scale. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured.The VAS is the most frequently used method to assess pain intensity. The scale will be displayed as a horizontal 10-cm line labelled at each end by descriptors such as 'no pain' (the minimum and best outcome possible) and 'worse pain ever' (maximum and worst outcome possible). The participant will mark the line to indicate pain severity and it is simply quantified by measuring the distance in centimeters from 0 (no pain) to the patient's marked rating.

次要结局

  • Upper limb function(Changes from baseline (measured immediately before the application of the first treatment) and at 40 minutes after the application of the last treatment.)

研究者

发起方
Francisco Unda Solano
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Francisco Unda Solano

Biomedicine Doctorate Program Investigator

Universidad Europea de Madrid

研究点 (1)

Loading locations...

相似试验